SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. - ARWR

New York, New York--(Newsfile Corp. - March 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") (NASDAQ: ARWR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Arrowhead and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 17, 2022, Arrowhead issued a press release announcing, "interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company's investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC)." Although characterizing the results as "positive", Arrowhead disclosed that "[f]ive serious AEs [adverse events] in 5 patients were reported by investigators as possibly drug related, including myocarditis (in a patient with a history of TKI induced cardiomyopathy), demyelinating neuropathy (in a patient with autoimmune sequelae due to checkpoint inhibitors), chronic inflammatory demyelinating polyradiculoneuropathy (in a patient with distant history of checkpoint inhibitor use), hypoxia (in a patient with a pulmonary infiltrate), and acute hypoxemic respiratory failure (in a patient with progressive lung metastatic disease)." On this news, Arrowhead's stock price fell sharply during intraday trading on February 17, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115496